Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Welcome to $ARLZ.... can't believe it went down on the investor conference NEWS, but probably just in sympathy with the market in general... Oh well, I think this one is just one to put away and look at in a couple of years over $10.... GLTY
I feel so guilty, buy 10,000 between 1.68 and 1.70 Thank You
Morning PR Announcement Arales to Present at the 2018 BIO CEO And Invester Conference in NYC February 12 and 13th .. Should be an eye opener
Nice plateau chart at higher levels.... $ARLZ
Good first day of trading for the NEW YEAR... Let's see where this goes...
Happy NEW YEAR ARLZ... now that tax loss selling season is over, let's see if this company rebounds... the NEWS is good...
Yep, someone is loading bigly down here...
Insiders buying - Institutions Buying - FUNDS BUYING- $ARLZ is a keeper... Thanks for the link!
https://www.americanbankingnews.com/2017/12/12/aralez-pharmaceuticals-inc-arlz-director-purchases-73500-00-in-stock.html
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Director Arthur S. Kirsch acquired 50,000 shares of the company’s stock in a transaction on Friday, December 8th. The shares were purchased at an average cost of $1.47 per share, with a total value of $73,500.00. Following the completion of the purchase, the director now directly owns 271,609 shares of the company’s stock, valued at $399,265.23. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Aralez Pharmaceuticals Inc. (NASDAQ ARLZ) opened at $1.43 on Tuesday. The company has a quick ratio of 0.92, a current ratio of 1.00 and a debt-to-equity ratio of 4.64. Aralez Pharmaceuticals Inc. has a one year low of $0.95 and a one year high of $5.17.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.02. The company had revenue of $24.30 million during the quarter, compared to analyst estimates of $22.87 million. Aralez Pharmaceuticals had a negative net margin of 112.89% and a negative return on equity of 118.13%. Aralez Pharmaceuticals’s quarterly revenue was up 78.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.32) earnings per share. equities research analysts expect that Aralez Pharmaceuticals Inc. will post -1.54 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the company. Brown Advisory Securities LLC purchased a new stake in shares of Aralez Pharmaceuticals during the third quarter valued at $394,000. Intrinsic Edge Capital Management LLC purchased a new stake in shares of Aralez Pharmaceuticals during the second quarter valued at $270,000. Ballentine Partners LLC boosted its stake in shares of Aralez Pharmaceuticals by 166.7% during the third quarter. Ballentine Partners LLC now owns 80,000 shares of the company’s stock valued at $183,000 after purchasing an additional 50,000 shares during the period. GSA Capital Partners LLP boosted its stake in shares of Aralez Pharmaceuticals by 88.5% during the second quarter. GSA Capital Partners LLP now owns 541,795 shares of the company’s stock valued at $731,000 after purchasing an additional 254,400 shares during the period. Finally, Isthmus Partners LLC boosted its stake in shares of Aralez Pharmaceuticals by 0.8% during the second quarter. Isthmus Partners LLC now owns 154,387 shares of the company’s stock valued at $208,000 after purchasing an additional 1,285 shares during the period. 19.60% of the stock is owned by hedge funds and other institutional investors.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
The stock moved nicely higher as investors begin to see that next year, $ARLZ will be self sustaining and profitable, imo.... GLTA
That's a question for their IR... I'm not sure... and not concerned at this point...
100 million mixed shelf ???
Sorry they filed for a 100 mixed slelf on Nov. 9th , would you know if any of that Shelf was done, appreciate your reply, shareholder
I'm sorry, I'm not clear what you are asking...
Any Info on Proposed Raise ?
Revenues projected-to-rise-from 100-million-dollars-to-150-million-Dollars, with EBDITA profits rising from net neutral 0 dollars to about 50 million dollars is really exciting.... I think anyone getting this stock in the $1.50 level will do very well. GLTA
Very-nice-new-INVESTOR-PRESENTATION-out! 2018-BIG-PROFIT-Projections
http://ir.aralez.com/phoenix.zhtml?c=254163&p=irol-presentations
Here are a couple of highlights..
The company is projecting REVENUES will increase 50% from 100 million dollars in 2017 to 150 million dollars in 2018! And the company will go from EBDITA neutral in 2017 to about 50 MILLION DOLLARS in 2018!
Their products are showing very hefty SALES INCREASES now... This stock should be a WINNER in 2018...
$ARLZ-NASDAQ-Pharma-$1.51-Aralez Announces Departure of Chief Financial Officer
Today 5:00 PM ET (PR NewsWire)Print
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced that Scott J. Charles, Chief Financial Officer, is leaving the Company to pursue other opportunities, effective immediately. Michael Kaseta will assume the position of Interim Chief Financial Officer ("CFO") along with his current duties as Corporate Controller. Mr. Kaseta has served as Corporate Controller since 2016 and brings a breadth of experience in all aspects of the Company's financial operations. Prior to joining Aralez, Mr. Kaseta served as CFO of Sanofi North America, Global Services.
"The Board and I want to wish Scott the best in his future endeavors," said Adrian Adams, Chief Executive Officer of Aralez. "We have full confidence in Mike's ability to lead our finance operations, and we expect a seamless transition. As outlined in our recent third quarter press release, we are now positioning the Company for the next phase of growth as illustrated in our updated 2017 financial guidance and preliminary 2018 outlook. We are confident that we are on the pathway to achieve sustained profitability and growth as we execute on our goals to deliver shareholder value."
About Aralez Pharmaceuticals Inc.Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular and other specialty areas. Aralez's Global Headquarters is in Ontario, Canada, the U.S. Headquarters is in Princeton, New Jersey and the Irish Headquarters is in Dublin, Ireland. More information about Aralez can be found at www.aralez.com.
Aralez Pharmaceuticals US Inc. Contact: Nichol L. OchsnerExecutive Director, Investor Relations & Corporate Communications732-754-2545nochsner@aralez.com
I agree - I've been in other Pharmaceutical Stocks that were turning the corner from not profitable, to profitable, and did very well. $ARLZ is one to just hold a couple of years for a 10 bagger from here, imo...
We are about to make some $$ here. Happy Thanksgiving. ??
$ARLZ $1.65+6% -Nasdaq-Pharma-BULLISH-ENGULFING reversal noted...
https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=ARLZ
https://finance.yahoo.com/news/aralez-announces-third-quarter-2017-120000493.html
Aralez Announces Third Quarter 2017 Financial Results And Achieves Profitability on an Adjusted EBITDA Basis for the First Time in the Third Quarter
BUY and STRONG BUY - Nice!
I'm looking to add if it goes to $1.50 - with the company about to become profitable and over 100 million dollars in revenues - this is certainly a NOBRAINER, imo...
Analysts reports coming.. let’s see what happens
3$ coming boom :))
As of September 30, 2017, approximately 66.8 million of the Company's common shares were issued and outstanding and the Company had cash and cash equivalents of approximately $40.7 million. The Company currently believes it has sufficient cash to fund operations for the next 12 months and beyond.
Given solid move today, 2.50 break is going to break
Any link to that analyst report.... What a nice move today!
ARLZ strong close today. Perfect day.
Sub 2dollars gone today imo
Will history repeat itself here with historical surprise of 20%? I will take that bet with nov call options
Cha ching
3dollars likely after reading analyst reports.. majority agrees earnings to outperform. Nov 2$ call option gold ;)))
Looking good today nice bounce
Results come out Nov. 9th... Still not expecting profits, but a nice decrease in losses would make the stock trade higher, imo...
It bottomed up premarket today we will see $3 or more here.
nice bounce today looks like we might be revisiting the 3 dollar range next week
Yeah nice work but yeah money to be made for sure BOL
How did you like my top call at $2.93? I'm going to watch the RSI and buy back in when I get the signal...
took some off the top still have half the position
* * $ARLZ Video Chart 10-03-17 * *
Link to Video - click here to watch the technical chart video
Glad I held my position
Followers
|
26
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
470
|
Created
|
02/05/16
|
Type
|
Free
|
Moderators |
Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada, Ireland, and the United States. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It offers Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; Soriatane, a retinoid, an aromatic analog of vitamin A for the treatment of severe psoriasis and other disorders of keratinization; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. It also markets NeoVisc, a sodium hylauronic solution; Uracyst, a sodium chondroitin sulfate; Durela, a tramadol hydrochloride; Proferrin, a heme iron polypeptide; Resultz, a isopropyl myristate; Collatamp G, a collagen-gentamycin; and a portfolio of eight products targeted for the areas of gastroenterology and women?s health. In addition, it develops YOSPRALA 81/40 and 325/40 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, which have completed Phase III clinical development in the United States; and Bilastine, an antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria. Further, its out-licensed products include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company is headquartered in Milton, Canada.
Aralez Pharmaceuticals Inc.’s ISS Governance QualityScore as of March 2, 2017 is 6. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 4; Compensation: 9.
151 Steeles Avenue East
Milton, ON L9T 1Y1
Canada
905-876-1118
http://www.aralez.com
Sector:
Industry:
Full Time Employees:
Name | Title | Pay | Exercised | Age |
---|---|---|---|---|
Mr. Adrian Adams | Chief Exec. Officer and Director | 1.02M | N/A | 66 |
Mr. Andrew I. Koven | Pres and Chief Bus. Officer | 683.18k | N/A | 59 |
Mr. Scott J. Charles | Chief Financial Officer | 653.07k | N/A | 42 |
Mr. Mark A. Glickman | Chief Commercial Officer | 504.94k | N/A | 51 |
Mr. John E. Barnhardt CPA | Principal Accounting Officer and VP of Fin. & Admin. | N/A | N/A | 67 |
SHARE THIS ARTICLE
-First Quarter 2017 Net Revenues of $26.0 Million-
-Cost Savings Plan Expected to Reduce 2017 Expenses by $23.0 Million; Improved 2017 Adjusted EBITDA Guidance-
-Currently Implementing a Bold Program Aimed at Allowing All Patients to Access Yosprala for Only $10.00 Per Month-
MISSISSAUGA, Ontario, May 9, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced financial results for the first quarter ended March 31, 2017. The Company also highlighted certain recent corporate and commercial achievements. All figures are in U.S. dollars.
"We are pleased to report a solid first quarter of 2017, together with important updates to our business addressing a number of the challenges we face," said Adrian Adams, Chief Executive Officer of Aralez. "We are making a bold and significant change to our pricing strategy for Yosprala® aimed at allowing all patients to access the product for only $10.00 per month. In addition, we continue to implement our cost savings plan to further improve our cost structure and balance sheet to maximize and preserve our financial flexibility. Our updated financial guidance for 2017 reflects our commitment to reaching break-even on an Adjusted EBITDA basis this year. We also continue to opportunistically look at business development opportunities with a strong focus on value creating and transformative M&A with the goal of enhancing shareholder value."
Company Highlights:
"Deerfield Partners remains fully supportive of Aralez and its management team as the company navigates its way through recent challenges," said James Flynn, Managing Partner at Deerfield. "We are encouraged by the new pricing strategy for Yosprala and the prospects for Zontivity."
Cost Savings Initiatives
The Company previously announced in April 2017 that it had begun implementing cost savings initiatives as part of the Company's ongoing objective to maximize value from its assets and preserve financial flexibility. The total expected operating expense reduction in 2017 of approximately $23.0 million includes the previously announced 32% reduction in its U.S. sales force, which is expected to yield 2017 savings of approximately $5.5 million ($7.5 million on an annual basis), a decrease of approximately $9.0 million in 2017 commercial spend, which primarily relates to non-direct marketing spend on Yosprala, and decreased 2017 departmental expenses across the business of approximately $8.5 million. While Aralez has made significant reductions to its expenses, the Company plans to invest an additional $7.0 million to support a successful phased launch of Zontivity that commenced on April 24, 2017, which the Company views as an increasingly attractive opportunity. The Company also continues to assess various business development opportunities with the goal of providing improved cash flow and an enhanced platform for creating value.
First Quarter 2017 Financial Results
Aralez's financial results for the three months ended March 31, 2016 include the operations of Tribute Pharmaceuticals Canada Inc. (Tribute) from February 5, 2016, the closing date of the Pozen and Tribute merger transaction (the Merger), through March 31, 2016, but do not include the results of Zontivity or Toprol-XL and its currently marketed authorized generic (the Toprol-XL franchise) as these acquisitions were completed on September 6, 2016 and October 31, 2016, respectively. Aralez's financial results for the three months ended March 31, 2017 include the results of Tribute, Zontivity and the Toprol-XL franchise.
Total revenues for the three months ended March 31, 2017 were $26.0 million compared to $8.1 million for the three months ended March 31, 2016. Net product revenues of $6.7 million for the three months ended March 31, 2017 primarily related to the product portfolio acquired with the acquisition of Tribute as well as net product revenues from Yosprala and Fibricor®. Other revenues of $19.3 million for the three months ended March 31, 2017 were comprised of net revenues of $15.6 million from the acquisitions of the Toprol-XL franchise and Zontivity, which are recorded net of related cost of product revenues and fees paid during the respective transition service periods, and Vimovo® royalties of $3.7 million. Pursuant to the Company's agreement with Horizon in the U.S., subject to certain conditions described in our public filings, Aralez is guaranteed a quarterly minimum royalty amount (calculated based on a minimum annual royalty of $7.5 million), which was reflected in the Company's first quarter results. Net product revenues of $3.6 million for the three months ended March 31, 2016 related to the Tribute product portfolio acquired in the Merger, which was completed on February 5, 2016. Other revenues of $4.5 million for the three months ended March 31, 2016 were comprised solely of Vimovo royalties.
Cost of product revenues were $2.8 million for the three months ended March 31, 2017 compared to $2.5 million for the three months ended March 31, 2016. The increase related primarily to costs of product revenues for the full quarter in 2017 from the Company's product portfolio that was acquired as part of the Merger in February 2016.
SG&A expenses were $30.8 million for the three months ended March 31, 2017 compared to $37.5 million for the three months ended March 31, 2016. The decrease in SG&A expenses was primarily driven by costs related to the Merger in the prior year of approximately $19.4 million, partially offset by increased costs related to the build out of our U.S. sales force in 2016 and increased promotional expenses in the U.S. during the first quarter of 2017.
R&D expenses for the three months ended March 31, 2017 were $0.1 million compared to $4.4 million for the three months ended March 31, 2016. The decrease related primarily to higher costs incurred in the first quarter of 2016 for Yosprala in advance of its U.S. approval in September 2016.
Amortization of intangible assets of $8.5 million for the three months ended March 31, 2017 related to the acquisitions of Tribute, Zontivity and the Toprol-XL franchise. Amortization of intangible assets for the three months ended March 31, 2016 of $1.3 million related solely to the acquisition of Tribute.
The change in fair value of contingent consideration of $4.4 million for the three months ended March 31, 2017 related to accretion for the Toprol-XL franchise and Zontivity acquisitions. There was no expense related to fair value changes in contingent consideration for the three months ended March 31, 2016.
Interest expense of $6.7 million for the three months ended March 31, 2017 was primarily attributable to the borrowing of $200 million under the Company's credit facility in the fourth quarter of 2016 in connection with the acquisitions of Zontivity and the Toprol-XL franchise and $75 million convertible notes. Interest expense of $0.3 million for the three months ended March 31, 2016 related to the $75 million convertible notes.
Other income, net for the three months ended March 31, 2017, was $0.4 million compared to $4.8 million for the three months ended March 31, 2016, a decrease of $4.4 million. The decrease principally related to a $4.6 million decrease in the fair value of the warrants liability acquired from Tribute during the prior year, offset by a $0.3 million gain from the sale of a building in London, Ontario during the three months ended March 31, 2017.
The net loss for the three months ended March 31, 2017 was $27.5 million, or $0.42 loss per share on a fully diluted basis, compared to a net loss for the three months ended March 31, 2016 of $33.8 million, or $0.73 loss per share on a fully diluted basis.
Adjusted EBITDA was ($3.6) million for the three months ended March 31, 2017 compared to Adjusted EBITDA of ($11.1) million for the three months ended March 31, 2016.
Balance Sheet
As of March 31, 2017, approximately 65.8 million of the Company's common shares were issued and outstanding and the Company had cash and cash equivalents of approximately $73.7 million.
Updated 2017 Guidance
Aralez's estimates are based on projected results of the Company for the year ending December 31, 2017 and reflect management's current beliefs and expectations about, among other things, prescription trends, competition, pricing levels, inventory levels, and anticipated future events. The Company's guidance on Adjusted EBITDA includes, among other things, costs to support the commercialization efforts with respect to Yosprala, Zontivity and the Canadian product portfolio as well as costs to support the global corporate structure. It excludes share-based compensation expense and certain discrete costs, including merger and product acquisition-related expenses. See "Use of Non-GAAP Financial Measures" below.
For the year ending December 31, 2017, assuming, among other factors more particularly set out in "Cautionary Note Regarding Forward-Looking Statements" below, the Company currently expects:
See the table below for a comparison of the Company's original 2017 guidance compared to the updated 2017 guidance:
Measure | 2017 Original Guidance | 2017 Updated Guidance |
Net Revenues | $80 million to $100 million | $80 million to $100 million |
Adjusted EBITDA | $(25) million to $(10) million | $(5) million to $5 million |
First Quarter Results Webcast
Aralez will host a webcast this morning, May 9, 2017 at 9:00 a.m. ET to present results for the first quarter 2017. The webcast can be accessed live and will be available for replay at www.aralez.com.
Conference Call Details
Date: Tuesday, May 9, 2017
Time: 9:00 a.m. ET
Dial-in (U.S.): 877-407-8037
Dial-in (International): 201-689-8037
About Aralez Pharmaceuticals Inc.
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in Ontario, Canada, the U.S. Headquarters is in Princeton, New Jersey and the Irish Headquarters is in Dublin, Ireland. More information about Aralez can be found at www.aralez.com.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |